FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2788005287> ?p ?o ?g. }

• W2788005287 endingPage "215" @default.
• W2788005287 startingPage "214" @default.
• W2788005287 abstract "The incidence and mortality of peptic ulcer rose markedly during the 19th century,1Sonnenberg A Review article: historic changes of Helicobacter pylori-associated diseases.Aliment Pharmacol Ther. 2013; 38: 329-342Crossref PubMed Scopus (63) Google Scholar peaking in the generation born at the end of the century, and then steadily decreasing. In recent decades, the main ulcer aetiology has shifted in many countries from Helicobacter pylori to non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin. Use of other drugs such as steroids, aldosterone antagonists, and selective serotonin reuptake inhibitors can contribute to gastroduodenal ulceration and its complications.2Masclee GMC Valkhoff VE Coloma PM et al.Risk of upper gastrointestinal bleeding from different drug combinations.Gastroenterology. 2014; 147: 784-792Summary Full Text Full Text PDF PubMed Scopus (109) Google Scholar This combination of factors explains why upper gastrointestinal bleeding remains the most common gastrointestinal emergency globally. In the USA, gastrointestinal bleeding led to 796 000 emergency department visits and 435 000 admissions in 2012, comprising 20% of gastrointestinal emergency admissions that year.3Peery AF Crockett SD Barritt AS et al.Burden of gastrointestinal, liver, and pancreatic diseases in the United States.Gastroenterology. 2015; 149: 1731-1741Summary Full Text Full Text PDF PubMed Scopus (590) Google Scholar Peptic ulcer is the predominant bleeding source, accounting for around 40% of upper gastrointestinal bleeds. Many occur in elderly people with comorbidity and multidrug use, which, combined with frequent presentation with shock, explains why ulcer bleeding remains associated with a 5–10% mortality despite improvements in management and care. This situation calls for primary prevention of ulcer formation and ulcer bleeding, improved management of a bleed, and prevention of rebleeding. Many studies have therefore focused on the effect of gastroprotection, in particular by means of proton-pump inhibitors (PPIs) as well as histamine-2 receptor antagonists and prostaglandin analogues. However, the abundance of studies and treatment regimens makes the effects of gastroprotection difficult to quantify. This challenge underlines the importance of the thorough, high-quality systematic review and meta-analysis4Scally B Emberson JR Spata E et al.Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: meta-analysis of randomised trials.Lancet Gastroenterol Hepatol. 2018; (published online Feb 20.)http://dx.doi.org/10.1016/S2468-1253(18)30037-2Summary Full Text Full Text PDF PubMed Scopus (110) Google Scholar of gastroprotectant drug trials published in The Lancet Gastroenterology & Hepatology. Benjamin Scally and colleagues analysed 1212 randomised trials of gastroprotectant drugs, including 849 trials of 142 485 participants that compared a gastroprotectant with control. All included trials focused on the effect of gastroprotection on peptic ulcer prevention, ulcer healing, and upper gastrointestinal bleeding. Scally and colleagues report substantial benefits, in particular with PPI treatment, in all three areas. Importantly, these effects were of similar magnitude in NSAID users and non-users, and did not differ between PPIs. PPI treatment was associated with an odds ratio of 0·20 (95% CI 0·17–0·23) for development of an endoscopic ulcer, of 0·21 (0·12–0·36) for an ulcer bleed, and of 5·22 (4·00–6·80) for ulcer healing. The comprehensive analysis also allowed an investigation of the effects of PPIs on further bleeding and complications. PPI treatment significantly reduced the risk of further bleeding, and the need for blood transfusion, endoscopic intervention, and surgery, with ORs ranging between 0·56 and 0·67. Previous individual trials have been unable to show any benefit of gastroprotection on all-cause mortality in bleeding patients, which is confirmed in this systematic review (OR 0·90, 95% CI 0·72–1·11). Scally and colleagues' findings support guideline recommendations for management of patients with upper gastrointestinal bleeding, including use of intravenous PPIs while awaiting (but not delaying) upper endoscopy, oral or intravenous PPIs immediately after endoscopy, and oral PPI maintenance in patients at high risk for rebleeding.5Gralnek IM Dumonceau J-M Kuipers EJ et al.Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.Endoscopy. 2015; 47: a1-a46Crossref PubMed Scopus (492) Google Scholar, 6Barkun AN Bardou M Kuipers EJ et al.International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding.Ann Intern Med. 2010; 152: 101-113Crossref PubMed Scopus (887) Google Scholar, 7Sung JJY Chan FKL Chen M et al.Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding.Gut. 2011; 60: 1170-1177Crossref PubMed Scopus (147) Google Scholar Do these findings also provide definite answers to all clinical issues regarding gastroprotectants? The answer is no. Despite the large number of trials, the median number of patients per trial was only 78 (IQR 44·0–210·5) and the median duration only 1·4 months (IQR 0·9–2·8).4Scally B Emberson JR Spata E et al.Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: meta-analysis of randomised trials.Lancet Gastroenterol Hepatol. 2018; (published online Feb 20.)http://dx.doi.org/10.1016/S2468-1253(18)30037-2Summary Full Text Full Text PDF PubMed Scopus (110) Google Scholar These small numbers explain why the number of events in subgroup analyses was low for some of the outcomes. These outcomes included rare complications such as complicated ulcer disease in non-NSAID users, but also events such as further bleeding, blood transfusion, and need for endoscopic and surgical intervention when analysed by drug class. The very short, 3-day median duration of the acute upper gastrointestinal bleeding trials probably also influenced the results. Furthermore, the analyses did not allow firm conclusions to be reached on the effect of high-dose PPIs when given orally or intravenously in patients with bleeding ulcers. Although initial studies focused on high-dose continuous intravenous therapy, recent data suggest that intermittent intravenous or frequent oral dosing are similarly effective.8Sachar H Vaidya K Laine L Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers.JAMA Intern Med. 2014; 174: 1755Crossref PubMed Scopus (110) Google Scholar, 9Tringali A Manta R Sica M Bassotti G Marmo R Mutignani M Comparing intravenous and oral proton pump inhibitor therapy for bleeding peptic ulcers following endoscopic management: a systematic review and meta-analysis.Br J Clin Pharmacol. 2017; 83: 1619-1635Crossref PubMed Scopus (18) Google Scholar The latest update of the Asia-Pacific guideline on upper gastrointestinal bleeding concluded that high-dose oral PPIs (defined as ≥80 mg daily) can be used to prevent rebleeding (unpublished data), albeit with the warning that available studies were relatively small and underpowered. The optimum method of dosing requires further study. In conclusion, the thorough meta-analysis by Scally and colleagues provides relevant information for many clinicians. It confirms that gastroprotection, in particular by means of PPIs, is associated with a roughly five times reduced risk of ulcer incidence as well as ulcer bleeds when compared with no protection, and a five times improvement in ulcer healing. It also points to areas that require further study, in particular the need to understand whether oral and intravenous PPIs are similarly effective in patients with bleeding ulcers to prevent rebleeding and to reduce the need for intervention including endoscopic treatment, transfusion, surgery, and prolonged admission. I declare no competing interests. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trialsGastroprotectants, in particular PPIs, reduce the risk of peptic ulcer disease and its complications and promote healing of peptic ulcers in a wide range of clinical circumstances. However, this meta-analysis might have overestimated the benefits owing to small study bias. Full-Text PDF Open Access" @default.
• W2788005287 created "2018-03-06" @default.
• W2788005287 creator A5081503066 @default.
• W2788005287 date "2018-04-01" @default.
• W2788005287 modified "2023-09-26" @default.
• W2788005287 title "PPIs for prevention and treatment of peptic ulcer" @default.
• W2788005287 cites W1222886474 @default.
• W2788005287 cites W1984907416 @default.
• W2788005287 cites W2109525960 @default.
• W2788005287 cites W2142903103 @default.
• W2788005287 cites W2143180816 @default.
• W2788005287 cites W2171316611 @default.
• W2788005287 cites W2219775147 @default.
• W2788005287 cites W2587635957 @default.
• W2788005287 cites W2788189477 @default.
• W2788005287 doi "https://doi.org/10.1016/s2468-1253(18)30047-5" @default.
• W2788005287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29475805" @default.
• W2788005287 hasPublicationYear "2018" @default.
• W2788005287 type Work @default.
• W2788005287 sameAs 2788005287 @default.
• W2788005287 citedByCount "4" @default.
• W2788005287 countsByYear W27880052872020 @default.
• W2788005287 countsByYear W27880052872022 @default.
• W2788005287 countsByYear W27880052872023 @default.
• W2788005287 crossrefType "journal-article" @default.
• W2788005287 hasAuthorship W2788005287A5081503066 @default.
• W2788005287 hasBestOaLocation W27880052871 @default.
• W2788005287 hasConcept C126322002 @default.
• W2788005287 hasConcept C17744445 @default.
• W2788005287 hasConcept C177713679 @default.
• W2788005287 hasConcept C199539241 @default.
• W2788005287 hasConcept C2779473830 @default.
• W2788005287 hasConcept C2780656511 @default.
• W2788005287 hasConcept C71924100 @default.
• W2788005287 hasConcept C90924648 @default.
• W2788005287 hasConceptScore W2788005287C126322002 @default.
• W2788005287 hasConceptScore W2788005287C17744445 @default.
• W2788005287 hasConceptScore W2788005287C177713679 @default.
• W2788005287 hasConceptScore W2788005287C199539241 @default.
• W2788005287 hasConceptScore W2788005287C2779473830 @default.
• W2788005287 hasConceptScore W2788005287C2780656511 @default.
• W2788005287 hasConceptScore W2788005287C71924100 @default.
• W2788005287 hasConceptScore W2788005287C90924648 @default.
• W2788005287 hasIssue "4" @default.
• W2788005287 hasLocation W27880052871 @default.
• W2788005287 hasLocation W27880052872 @default.
• W2788005287 hasLocation W27880052873 @default.
• W2788005287 hasLocation W27880052874 @default.
• W2788005287 hasLocation W27880052875 @default.
• W2788005287 hasOpenAccess W2788005287 @default.
• W2788005287 hasPrimaryLocation W27880052871 @default.
• W2788005287 hasRelatedWork W1980506963 @default.
• W2788005287 hasRelatedWork W1990758009 @default.
• W2788005287 hasRelatedWork W2065851541 @default.
• W2788005287 hasRelatedWork W2347832651 @default.
• W2788005287 hasRelatedWork W2406719928 @default.
• W2788005287 hasRelatedWork W2409276078 @default.
• W2788005287 hasRelatedWork W2417582986 @default.
• W2788005287 hasRelatedWork W2441786729 @default.
• W2788005287 hasRelatedWork W3041679829 @default.
• W2788005287 hasRelatedWork W3200983457 @default.
• W2788005287 hasVolume "3" @default.
• W2788005287 isParatext "false" @default.
• W2788005287 isRetracted "false" @default.
• W2788005287 magId "2788005287" @default.
• W2788005287 workType "article" @default.